September 27, 2016 6:11 PM ET

Biotechnology

Company Overview of Reliance Life Sciences Pvt. Ltd.

Company Overview

Reliance Life Sciences Pvt. Ltd. operates as a life sciences company. Its activities include researching, developing, and marketing plasma proteins, biosimilars, and proteins; developing active pharmaceutical ingredients and formulations, such as oncology products, steroids, hormones, and peptides; offering services, which include regulatory toxicity studies, bioavailability, pharmacokinetics, cardiac safety, mass balance studies, phase I to IV clinical trial management and monitoring, data management and biostatistics, and medical writing; and providing regenerative medicine, which include embryonic stem cells, ocular stem cells, haematopoietic stem cells, skin and tissue engineering, and a...

Dhirubhai Ambani Life Sciences Centre

R-282, TTC Area of MIDC

Thane-Belapur Road

Rabale

Navi Mumbai,  400 701

India

Founded in 2001

Phone:

91 22 6767 8000

Fax:

91 22 6767 8099

Key Executives for Reliance Life Sciences Pvt. Ltd.

Chief Executive Officer and President
Age: 58
President of U S Operations
General Manager of Corporate Communications
Compensation as of Fiscal Year 2016.

Reliance Life Sciences Pvt. Ltd. Key Developments

Reliance Lifesciences Launches First Biosimilar Used to Treat Advanced Cancers

Reliance Lifesciences has launched the biosimilar, or copies of bevacizumab, a complex medicine used to treat at least six forms of advanced cancers. Reliance's product is approved by the Indian regulator for use in cases of colorectal cancer. Swiss biotechnology powerhouse Roche is the innovator of bevacizumab and markets it globally as Avastin. The product had annual sales in excess of $7 billion last year. While Reliance will market the bevacizumab copies under its own brand name Bevacirel, it has also entered into a "principal-to-principal agreement" with Lupin. It had introduced a recombinant chorionic gonadotrophin hormone used in assisted reproduction, interferon beta for the treatment of multiple sclerosis, and reteplase, a drug used in the management of myocardial infarction. A Reliance official declined to comment on the development. Lupin did not respond uuntil the time of going to press. Reliance's bevacizumab is expected to compete with Roche's brand, but unlike most biosimilar launches, where the cut price versions are sold at roughly 25% discount over the innovator's price, market sources said Reliance has kept a minuscule gap between the price of its product and that of Roche. Roche's Avastin of 100 mg strength is learnt to be sold at about INR 29,500 while Reliance is likely to market its product at INR 28,300 per injection. For the 400 mg variant, Avastin is available at about INR 108,000 and Reliance's drug is sold at INR 105,000 for each injection. Market sources estimated the market at about INR 1,700, but added that a wider market footprint of Lupin and Reliance will accelerate the reach.

Delhi High Court Places Temporary Injunction Preventing Sales of Reliance's Biosimilar Trastuzumab

The Indian Delhi High Court has issued a temporary injunction banning Reliance (India) from launching a "biosimilar" version of Roche (Switzerland)'s breast cancer drug Herceptin (trastuzumab). The injunction follows a petition filed by Roche, which argues that Reliance's product is similar to Herceptin. The two companies have now been requested to submit written submissions within two weeks before the court is to hear the case.

Torrent Pharmaceuticals Ltd Enters into an Exclusive Licensing Agreement with Reliance Life Sciences

Torrent Pharmaceuticals Ltd. has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in the Indian market. Torrent Pharmaceuticals informed that Rituximab, Adalimumab and Cetuximab will be developed by Reliance Life Sciences and supplied to Torrent Pharma after obtaining all necessary regulatory approvals. Torrent Pharma will be the only company to market these biosimilars in India other than Reliance Life Sciences. According to the terms of agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for 10 years.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Reliance Life Sciences Pvt. Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.